Choosing the right path in clinical development – as in life – is a huge challenge.  For small companies it can be the difference between success and failure, survival and implosion.  But divergent clinical data published in the last month on two apparently similar members of the Factor Xa inhibitor class demonstrate that the largest pharma companies can get it wrong too – and the consequences for them may be no less catastrophic.More

RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to formal preclinical development and clinical up to Phase IIa. In the last five years, we have witnessed dramatic changes in the drug development …